SLT and MIGS evidence is procedure- and population-specific. After retinal surgery, treat the pressure mechanism and retinal ischaemia together.
Terminology and draft status
Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.
01SLT: select suitable eyes and interpret the trials
Selective laser trabeculoplasty (SLT) can be an initial or adjunct option in suitable open-angle disease. Cytokine signalling and trabecular remodelling explain a proposed biological mechanism; “no anatomical damage” is too absolute. 1 4 5
Inflammation, transient pressure rise and non-response remain possible, and lower baseline pressure may limit the absolute reduction. 1 4 5
LiGHT China is a separate trial, not a subgroup of the UK LiGHT study. Baseline age, myopia and severity affect applicability; a cohort comparison does not prove an ethnic treatment effect. 6 7
The repeat-SLT analysis selected 180 eyes of 105 participants and was post hoc, with different pretreatment pressures and no random allocation to initial versus repeat treatment. 6 7
In the UK exploratory analysis, secondary SLT followed at least 3 years of drops. Switching stable eyes reduced medication burden; escalating uncontrolled eyes could add pressure control but did not eliminate surgery. 8
These were different indications, not a randomised SLT-switch versus intensified-medication comparison. 8
The masked multicentre Swedish OSLT trial enrolled 400 patients and compared 180°/360° standard/high protocols. At 1–6 months, 360/high reduced pressure by 5.4 mmHg versus 3.4/3.2/4.2 mmHg; 6-month success was 58.3% versus 30.2/29.3/41.7%. 9
More transient discomfort accompanied the strongest protocol; this is not proof of superiority in every NTG eye. 9
Energy in OSLT was titrated to a tissue response rather than one fixed pulse setting. The lecture’s means 0.95 versus 0.71 mJ remain original values requiring their exact source; they are not a universal operative prescription. Repeat treatment, previous response, angle anatomy, pigmentation and pressure monitoring require individual assessment. 1 9
| Parameter | Trial/lecture context | Clinical meaning and limit |
|---|---|---|
| Extent | OSLT compared 180° and 360° with standard/high protocols | 360/high performed best in this trial; not a universal NTG result |
| Energy | Original means 0.95 versus 0.71 mJ remain unreconciled | Titrate to tissue response and device guidance; means are not mandatory settings |
| Repeat treatment | Effect can wane; repeat SLT is a separate decision | Assess angle, prior response, baseline pressure, follow-up and study selection |
02MIGS: distinguish mechanism, study design and applicability
Minimally invasive glaucoma surgery (MIGS) includes different mechanisms and devices; it is not one interchangeable intervention. HORIZON tested Hydrus added to cataract surgery against cataract surgery alone in selected POAG, not stand-alone surgery in NTG. 1 18
Weigh the required target, medication burden, cost, adverse effects and distal outflow rather than assuming a universal step between laser and filtration. 1 18
A 2026 systematic review of 16 MIGS RCTs with 4562 participants reported mean fragility index 9.4 and fragility quotient 0.031. It selected significant binary outcomes. Fragility is not effect size or proof that every device is ineffective; interpret it alongside attrition, uncertainty and the clinical comparison. 10
The Manchester study followed phacoemulsification plus a first-generation iStent without a control group: 41 patients entered and 19 remained at 84 months (7 years). 11
Reported pressure/drop reductions are limited by attrition, selection and cataract-surgery effects. They do not establish the same long-term benefit for every iStent model or NTG patient. 11
Pahlitzsch compared stand-alone SLT, Trabectome and iStent inject retrospectively using propensity matching and 3-year follow-up. Similar measured pressure outcomes do not establish equivalence. 12
Choice of procedure, residual confounding, differing eligibility and the success definition remain important when interpreting “no difference”. 12
The original “1–4% of participants” and “69% of trials change with fewer than 10 outcomes” are slide-derived statements requiring reconciliation with the named review and selected endpoints. They are not confidence intervals, effect sizes or a reason to dismiss every MIGS trial. 10 20
| Feature | SLT | Trabecular MIGS / bypass |
|---|---|---|
| Primary mechanism | Biological signalling/remodelling; a simplified model | Anatomical bypass or tissue removal; device-specific |
| Anatomy | No intentional incisional opening; not a guarantee of no tissue effects | Trabecular modification/bypass; distal outflow still matters |
| Lecture framing | Make trabecular outflow work better | Bypass part of the resistance; not proof that all outflow problems are solved |
03After retinal surgery: identify the pressure mechanism
Pressure elevation after pars plana vitrectomy (PPV) is secondary glaucoma context, not evidence for NTG. Timing, tamponade, inflammation, bleeding, steroid exposure and the drainage angle guide assessment. 1 15 17
The original day-one and first-week percentages use different thresholds and unresolved cohorts; they cannot be taught as one rising incidence curve. 1 15 17
The lecture orders gas expansion as C3F8 > C2F6 > SF6 > air. Preserve the mechanism, but do not turn this into a universal patient-risk ranking: concentration, fill volume, lens/angle anatomy and postoperative circumstances matter. Avoid overfill and assess a painful pressure spike promptly. 1 17
Silicone oil can cause pressure elevation through overfill, anterior migration, pupillary block, inflammation or emulsified droplets obstructing the trabecular meshwork. Long contact may leave persistent outflow damage. 1 16
A heterogeneous literature range for emulsification is not an individual risk estimate or proof of the same mechanism in every eye. 1 16
A retrospective 196-patient tamponade comparison reported consistently raised IOP with silicone oil at RR 4.70 (95% CI 1.86–11.85). Case mix, treatment selection and the outcome definition limit interpretation. 16
This is an association in a postoperative population, not an NTG trial or a universal forecast after oil injection. 16
Assess the lens, capsule, anterior hyaloid and patency/location of an iridectomy when pupillary block is possible. Aphakia and a disrupted lens barrier differ from uncomplicated pseudophakia. 1 17
The lecture’s universal inferior-iridectomy rule and closure percentage require their original operative context; they are not automatic instructions for every pseudophakic eye. 1 17
Treat pressure and inflammation according to the mechanism. Oil removal may help selected eyes but does not always reverse glaucoma and can increase retinal redetachment risk. 1
Conventional filtration has a poorer prognosis in these eyes, not certain failure; drainage devices or cyclophotocoagulation (CPC) may be alternatives, with their own complications and visual-potential considerations. 1
Neovascular glaucoma (NVG) requires treatment of retinal ischaemia as well as pressure. Examine iris and angle neovascularisation (NVI/NVA), peripheral anterior synechiae (PAS) and the retinal cause. 1 13
Clearing media does not stop the angiogenic drive; coordinate retinal photocoagulation and appropriate anti-VEGF treatment with glaucoma management. 1 13
In Sakamoto’s retrospective diabetic-vitrectomy cohort, selected model associations were NVI/NVA OR 3.93 (95% CI 1.05–14.65), insulin OR 2.09 (1.02–4.30) and tamponade OR 2.18 (1.13–4.23). 13
Wide intervals, confounding and variable selection matter. Odds ratios are not absolute patient risks or proof that tamponade causes the same risk in every eye. 13
Scott’s retrospective series combined PPV with drainage implants in 40 mixed refractory-glaucoma eyes, only 14 with NVG. Mean IOP fell from 34 to 13 mmHg at 1 year; 31/40 (77.5%) had stable/improved acuity. 14
Severe visual complications also occurred. Do not generalise these results as an Ahmed-only NVG trial. 14
The export reports 16.5% with IOP >21 mmHg on day 1 and 36% with IOP ≥24 mmHg within week 1, silicone-oil emulsification 0.7–56%, and inferior-iridectomy closure 11–32%. These unresolved denominators and definitions cannot be combined into one incidence curve or individual risk. Its proposed aqueous suppressants/steroids and possible oil removal depend on mechanism; steroids can themselves raise pressure. 20
04Make a joint plan and reassess the result
Before surgery, map optic nerve reserve, angle/PAS/NVI, lens status and conjunctival resources for later filtration. During surgery, plan tamponade concentration and fill, a suitable patent iridectomy when indicated, and retinal ischaemia treatment. 1 17
These are coordinated clinical decisions, not a universal operative recipe or a claim that clearing the media treats the underlying ischaemia. 1 17
RCOphth’s 2026 practice points support risk-adapted postoperative review, with very-low-certainty heterogeneous evidence. Some uncomplicated low-risk patients can omit postoperative day 1 review; glaucoma, comorbidity, tamponade and complicated surgery alter that decision. 15
Pressure prophylaxis, later review and clear emergency access must be planned; no patient should cancel a scheduled visit on the basis of this summary. 15
Continue early pressure checks when indicated, and reassess NVI/NVA and retinal perfusion in proliferative diabetic retinopathy (PDR). The original 1/3/6-month schedule is a teaching protocol, not a universal interval. 1 15 17
New pain, sudden visual loss or concerning neurological symptoms need urgent assessment; routine NTG follow-up and postoperative emergency care answer different questions. 1 15 17
The original Kwon/Sakamoto attribution includes onset around 5.8 months, which is not uniquely traced here. The suggested PDR checks at 1, 3 and 6 months and day 1/week 1 pressure checks remain lecture examples; individual risk, symptoms and the operation determine the actual schedule. Early drops or tamponade release requires specialist diagnosis, not an automatic home action. 20
| Original review topic | Evidence context | What should guide the decision? |
|---|---|---|
| SLT: China and UK | Separate trials and selected secondary analyses | Population, baseline pressure, severity and indication; do not infer ethnic superiority |
| SLT technique | OSLT standard/high and 180°/360° comparison | Clinical trial protocol is not a universal fixed-energy prescription |
| MIGS fragility | Selected statistically significant binary outcomes | Effect size, missing data and clinical importance alongside FI/FQ; original percentages require reconciliation |
| Silicone oil | Multiple pressure mechanisms; poorer filtration prognosis | No inevitable trabeculectomy failure; balance oil removal, retinal stability, GDD/CPC and visual potential |
| Post-PPV pressure spikes | Different thresholds, time windows, prophylaxis and case mix | Do not merge original percentages; gas risk depends on more than expansion order |
| NVG risk | Retrospective diabetic-vitrectomy associations | NVI/NVA, ischaemia, angle and retinal cause; original Kwon onset and timing still unresolved |
What guides the choice of intervention?
SLT and MIGS evidence is procedure- and population-specific. After retinal surgery, treat the pressure mechanism and retinal ischaemia together.
When is review urgent?
New pain, sudden visual loss, marked pressure rise or iris/angle neovascularisation needs urgent ophthalmic review.
References and access status
- 1EGS Terminology and Guidelines for Glaucoma,6th edition (2025)
Historical Review 010 access of 4 November 2026 reused; Supplied local PDF text: CNTGS pp44–45, POAG/risk pp124–125, treatment principles/target pp160–169 and vitreoretinal mechanisms p136; CCT p80 carried forward. Relevant passages only, not every figure/table or whole-book reading. DOI10.1136/bjophthalmol-2025-egsguidelines.
- 2CNTGS effectiveness/intent-to-treat report (1998),DOI10.1016/S0002-9394(98)00272-4
Historical Review 010 access of 4 November 2026 reused; Complete indexed primary abstract read; main paper/supplements unread. Selection, cataract censoring and different denominators retained. Companion report not newly read in full; no silent reconciliation with EGS summary.
- 3Charlson et al. Nocturnal hypotension and glaucoma progression (2014)
Historical Review 010 access of 4 November 2026 reused; Primary indexed abstract access carried forward from Review 009; full report unread. Observational association, not a trial of adjusting systemic treatment.
- 4LiGHT six-year UK trial (2023)
Historical Review 010 access of 4 November 2026 reused; Abstract appraisal carried forward from Review 008; not newly read full text. Read with the2025 corrigendum; superseded surgery counts are not repeated as current evidence.
- 5LiGHT corrigendum (2025),DOI10.1016/j.ophtha.2025.07.029
Historical Review 010 access of 4 November 2026 reused; Publisher-indexed correction access carried forward from Review 008. Complete corrected tables/pp1323–1325 still unread after direct403; no full-correction validation claimed.
- 6LiGHT China design and baseline characteristics (2021)
Historical Review 010 access of 4 November 2026 reused; Primary baseline report located and indexed passages inspected; full PDF not read. Separate Chinese trial, not a UK subgroup or direct ethnic-effect comparison.
- 7LiGHT China: responsiveness/repeat SLT (2024)
Historical Review 010 access of 4 November 2026 reused; Complete primary abstract, selected methods/results and extracted tables inspected. Full narrative not completely read; supplements/figure pixels unread. Post hoc selected-eye analysis with multiplicity and eye-dependence limits.
- 8LiGHT: secondary SLT after medical treatment (2025)
Historical Review 010 access of 4 November 2026 reused; Complete primary abstract and selected methods/statistical/limitation passages read. Main report not fully read; supplements unread. Switch/escalation indications were not randomised against each other.
- 9Dahlgren et al. Swedish OSLT RCT (2024),DOI10.1016/j.ogla.2023.10.004
Historical Review 010 access of 4 November 2026 reused; Complete primary abstract directly read; full report/rare-harm estimates unread. Titrated protocols; original exact mean energies need their source. The2025 predictor paper is post hoc, not independent replication.
- 10Ansari et al. MIGS fragility systematic review (2026),DOI10.1016/j.ajo.2026.02.024
Historical Review 010 access of 4 November 2026 reused; Complete primary abstract directly read; full methods/tables/registration unread. Restricted to selected significant binary outcomes; FI/FQ do not replace effect sizes or risk-of-bias appraisal.
- 11Ziaei and Au. Manchester iStent seven-year cohort
Historical Review 010 access of 4 November 2026 reused; Accessible primary abstract, narrative results/limitations and extracted table1 read; figure pixels/supplements unread. Abstract/body reductions and a table percentage differ; discrepancies remain in evidence.md. Uncontrolled combined surgery and attrition limit causal inference.
- 12Pahlitzsch et al. SLT versus MIGS (2021),DOI10.1007/s40123-021-00347-0
Historical Review 010 access of 4 November 2026 reused; Complete primary abstract directly read; selected indexed main-text description only. Full PMC access challenged. Retrospective matching, residual confounding and differing abstract/figure success thresholds noted.
- 13Sakamoto et al. NVG after diabetic vitrectomy (2018),DOI10.2147/OPTH.S184959
Historical Review 010 access of 4 November 2026 reused; Indexed primary tables inspected; direct PubMed incomplete/publisher403. Full methods/report unread. Model selection, confounding, wide intervals and odds versus absolute risk retained.
- 14Scott et al. Combined PPV and drainage implants (2000),DOI10.1016/S0002-9394(99)00363-3
Historical Review 010 access of 4 November 2026 reused; Complete indexed primary abstract read; direct retrieval incomplete. Main article unread. Mixed refractory-glaucoma case series, not uniformly NVG/Ahmed; serious visual harms and selection matter.
- 15RCOphth. Day-one review in modern vitrectomy surgery (January2026)
Historical Review 010 access of 4 November 2026 reused; Main pp1–3 read and p4 flowchart visually inspected from locally rendered official PDF. Appendix tables not fully inspected. Very-low-certainty evidence; conditional risk-based review, not a universal omission or mandatory regimen.
- 16Endotamponade comparison: retrospective196-patient study (2019)
Historical Review 010 access of 4 November 2026 reused; Indexed primary result passage inspected; direct PMC challenged; full report unread. Distinguish persistently raised pressure from any rise. Exact comparator, definitions and confounding need the full report.
- 17Historical review 010 source-access ledger; original derivative lecture
Historical Review 010 access of 4 November 2026 reused; Complete existing German page and companion topic read; original snapshot and all three tables retained. Videos, spoken transcript and slides not inspected; no exact spoken-term verification claimed.
- 18HORIZON five-year randomised trial (2022),DOI10.1016/j.ophtha.2022.02.021
Historical Review 010 access of 4 November 2026 reused; Primary indexed abstract design/population passages inspected; full report/supplements not newly read here. Hydrus plus cataract surgery versus cataract surgery alone, not an NTG-specific stand-alone comparison.
- 19Kosior-Jarecka et al. Atypical NTG neuroimaging (2020),DOI10.1155/2020/9093206
Historical Review 010 access of 4 November 2026 reused; Complete primary abstract directly read; full report unread. Selected atypical patients: imaging yield cannot be applied to all routine NTG. Targeted differential work-up, not automatic MRI/lumbar puncture.
- 20Immutable original export; strategic glaucoma examination lecture
Complete export read; original attribution and any recording/transcript or appointment not independently verified.
For patients
Laser, drops and operations have different goals and risks; a joint retina/glaucoma plan can protect vision and reduce treatment burden.
Examination and selected tests guide individual treatment and follow-up; this educational text cannot replace your own assessment.
New pain, sudden visual loss, marked pressure rise or iris/angle neovascularisation needs urgent ophthalmic review.
New pain, sudden visual loss, marked pressure rise or iris/angle neovascularisation needs urgent ophthalmic review.